Ptácek L J, Tawil R, Griggs R C, Engel A G, Layzer R B, Kwieciński H, McManis P G, Santiago L, Moore M, Fouad G
Department of Neurology, University of Utah Health Sciences Center, Salt Lake City 84132.
Cell. 1994 Jun 17;77(6):863-8. doi: 10.1016/0092-8674(94)90135-x.
Hypokalemic periodic paralysis (hypoKPP) is an autosomal dominant skeletal muscle disorder manifested by episodic weakness associated with low serum potassium. Genetic linkage analysis has localized the hypoKPP gene to chromosome 1q31-q32 near a dihydropyridine (DHP) receptor gene. This receptor functions as a voltage-gated calcium channel and is also critical for excitation-contraction coupling in a voltage-sensitive and calcium-independent manner. We have characterized patient-specific DHP receptor mutations in 11 probands of 33 independent hypoKPP kindreds that occur at one of two adjacent nucleotides within the same codon and predict substitution of a highly conserved arginine in the S4 segment of domain 4 with either histidine or glycine. In one kindred, the mutation arose de novo. Taken together, these data establish this DHP receptor as the hypoKPP gene. We are unaware of any other human diseases presently known to result from DHP receptor mutations.
低钾性周期性麻痹(hypoKPP)是一种常染色体显性遗传性骨骼肌疾病,表现为与血清低钾相关的发作性肌无力。基因连锁分析已将hypoKPP基因定位到1号染色体q31-q32区域,靠近二氢吡啶(DHP)受体基因。该受体作为电压门控钙通道发挥作用,并且以电压敏感和钙非依赖的方式对兴奋-收缩偶联也至关重要。我们已对33个独立的hypoKPP家系中的11名先证者的患者特异性DHP受体突变进行了特征分析,这些突变发生在同一密码子内相邻的两个核苷酸之一,并预测在结构域4的S4片段中高度保守的精氨酸被组氨酸或甘氨酸取代。在一个家系中,该突变是新发的。综合这些数据,确定该DHP受体为hypoKPP基因。我们不知道目前已知有任何其他人类疾病是由DHP受体突变引起的。